3342 Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE study
Johan Hansson(Karolinska University Hospital), Axel Hauschild(Kiel University), A. Fittipaldo(Roche (United Kingdom)), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), R. Kuntsfeld, Lisa Licitra(University of Milan), Richard Dummer, Thomas Jouary(Hôpital Saint-André), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Nicole Basset‐Séguin(Inserm), Kate Fife(Addenbrooke's Hospital), Jean‐Jacques Grob, B. Guillot(Université de Montpellier), D. Scott Ernst, Laurent Mortier, Nicole Meyer(Université Toulouse III - Paul Sabatier), Yeun Mi Yim(Genesys (United States)), Brigitte Dréno(Inserm), Karen Bartley(Genesys (United States)), Sophie Williams
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k